Head-To-Head Analysis: Abaxis (ABAX) against Cubic (CUB)

Zoetis Inc

Zoetis Inc

D E Shaw reported 0% in Abaxis, Inc. Cubic pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. Tiaa Cref Inv Mgmt Limited Liability Corp accumulated 67,755 shares.

On 1/25/2018 NASDAQ:ABAX - Abaxis announced a quarterly dividend of $0.16 0.91% with an ex dividend date of 2/28/2018 which will be payable on 3/15/2018.

In related news, VP Craig Tockman sold 1,650 shares of the business's stock in a transaction that occurred on Wednesday, January 31st. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 820 shares or 0% of the stock.

Several analysts have released their opinion on Abaxis, Inc. Market capitalization is calculated by multiplying a company's shares outstanding by the current market price of one share. Barclays Pcl reported 0% of its portfolio in Abaxis, Inc. (NASDAQ:ABAX). Royal Bank & Trust Of Canada stated it has 473,511 shares. Gotham Asset Management LLC bought a new position in shares of Abaxis in the fourth quarter worth approximately $203,000.

On Wednesday, Shares of Abaxis, Inc. flaunted 16.15% to reach at $83.34 during previous trading session. (NASDAQ:ABAX). Gemmer Asset Mngmt Ltd Liability Corporation owns 96 shares. The company now has an average volume of 144.43 Million. The insider SINGH PRITHIPAL sold $149,255. On Tuesday, March 6 ARON KENNETH sold $98,266 worth of Abaxis, Inc. CASEY MICHAEL D sold 5,000 shs worth $355,327.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. (NASDAQ:ABAX). The Pennsylvania-based Vanguard Group Inc has invested 0% in Abaxis, Inc.

Abaxis Inc
Abaxis Inc

Total analysts of 7 have positions in Abaxis (NASDAQ:ABAX) as follows: 1 rated it a "Buy", 1 with "Sell" and 5 with "Hold". The recent change has given its price a 17.16% lead over SMA 50 and 6.13% lead over its 52-week high. 14% are bullish. With $90.0 highest and $48 lowest PT Abaxis has $65 average PT or -22.01% below the current ($83.34) price. Abaxis had 10 analyst reports since November 30, 2017 according to SRatingsIntel. On Friday, April 27 Stifel Nicolaus maintained Abaxis, Inc.

1/5/2018-Northcoast Research Upgrade from a "Neutral ➝ Buy" rating to a " rating. On Monday, January 29 the stock has "Buy" rating by Northcoast. In Tuesday, January 16 report Canaccord Genuity maintained it with "Hold" rating and $55.0 target. (NASDAQ:ABAX) has "Hold" rating given by Stifel Nicolaus. The company was maintained on Friday, January 26 by Stephens. (NASDAQ:ABAX) earned "Hold" rating by Canaccord Genuity.

ABAX hit $83.34 during the last trading session after $11.59 change.Abaxis, Inc.is uptrending after having risen 44.47% since May 17, 2017. The company had a trading volume of 71,177 shares, compared to its average volume of 112,918. (NASDAQ:ABAX)'s P/E ratio is 62.85. ABAX outperformed the S&P 500 by 32.92%.

Analysts await Abaxis, Inc. (NASDAQ:ABAX) will be acquired by the animal health company Zoetis Inc. The consensus mean EPS for the current quarter is at $0.35 derived from a total of 10 estimates from the analysts who have weighed in on projected earnings. After $0.42 EPS report previous quarter, Wall Street now sees -16.67 % negative EPS growth of Abaxis, Inc. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. The company has market cap of $1.89 billion. It operates in two divisions, Medical Market and Veterinary Market.The P/E ratio is 77.17.

Its quick ratio for most recent quarter is 4.90 along with current ratio for most recent quarter of 5.90. $333,460 worth of Abaxis, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Latest News